These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6639407)

  • 21. Pergolide in late-stage Parkinson disease.
    Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
    Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pergolide mesylate and idiopathic Parkinson disease.
    Tanner CM; Goetz CG; Glantz RH; Glatt SL; Klawans HL
    Neurology; 1982 Oct; 32(10):1175-9. PubMed ID: 6889702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the evaluations: or how to weigh the scales of parkinsonian disability.
    Diamond SG; Markham CH
    Neurology; 1983 Aug; 33(8):1098-9. PubMed ID: 6683814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term experience with pergolide therapy of advanced parkinsonism.
    Kurlan R; Miller C; Levy R; Macik B; Hamill R; Shoulson I
    Neurology; 1985 May; 35(5):738-42. PubMed ID: 3887213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pergolide mesylate in the treatment of Parkinson's disease resistant to other treatments. First Italian experience].
    Pezzoli G; Zecchinelli A; Mariani C; Reganati P; Scarlato G
    Clin Ter; 1991 Jan; 136(1):39-45. PubMed ID: 1826872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pergolide in the treatment of Parkinson's disease.
    Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
    Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
    [No Abstract]   [Full Text] [Related]  

  • 27. Suppression of REM rebound by Pergolide.
    Askenasy JJ; Yahr MD
    J Neural Transm; 1984; 59(2):151-9. PubMed ID: 6726217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of advanced Parkinson disease with pergolide.
    Lieberman A; Goldstein M; Leibowitz M; Neophytides A; Kupersmith M; Pact V; Kleinberg D
    Neurology; 1981 Jun; 31(6):675-82. PubMed ID: 7195484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of pergolide and mesulergine.
    Lieberman AN; Gopinathan G; Neophytides A
    Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease.
    Leibowitz M; Lieberman AN; Neophytides A; Gopinathan G; Goldstein M
    Adv Neurol; 1983; 37():121-30. PubMed ID: 6858770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind assessment of potential pergolide-induced cardiotoxicity.
    Kurlan R; Miller C; Knapp R; Murphy G; Shoulson I
    Neurology; 1986 Jul; 36(7):993-5. PubMed ID: 3520383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Painful dystonic spasms in Parkinson's disease.
    Ilson J; Fahn S; Côté L
    Adv Neurol; 1984; 40():395-8. PubMed ID: 6695618
    [No Abstract]   [Full Text] [Related]  

  • 34. Pergolide mesylate: new therapy for Parkinson disease.
    Tanner CM; Klawans HL
    Ann Intern Med; 1982 Apr; 96(4):522-3. PubMed ID: 7065569
    [No Abstract]   [Full Text] [Related]  

  • 35. Parkinson's disease: new drugs help but no cure on the horizon.
    González ER
    JAMA; 1981 Jul; 246(1):11-2. PubMed ID: 7241717
    [No Abstract]   [Full Text] [Related]  

  • 36. Further studies with pergolide in Parkinson disease.
    Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E; Nelson J
    Neurology; 1982 Oct; 32(10):1181-4. PubMed ID: 6889703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
    Navan P; Bain PG
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):602-3. PubMed ID: 12397168
    [No Abstract]   [Full Text] [Related]  

  • 39. One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
    Diamond SG; Markham CH
    Adv Neurol; 1984; 40():537-9. PubMed ID: 6695633
    [No Abstract]   [Full Text] [Related]  

  • 40. Pergolide and lisuride for Parkinson's disease.
    Lieberman AN; Leibowitz M; Neophytides A; Kupersmith M; Mehl S; Kleinberg D; Serby M; Goldstein M
    Lancet; 1979 Nov; 2(8152):1129-30. PubMed ID: 91856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.